Fezolinetant in the treatment of vasomotor symptoms associated with menopause-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Published:2021-07-03 Issue:7 Volume:30 Page:681-694
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Depypere Herman¹,Lademacher Christopher²,Siddiqui Emad³,Fraser Graeme L⁴

Affiliation:

1. Breast and Menopause Clinic, University Hospital, Ghent, Belgium

2. Global Development, Astellas Pharma Global Development, Northbrook, IL, USA

3. Medical Affairs, Astellas Pharma Medical and Development, Chertsey, UK

4. Former Chief Scientific Officer of Ogeda SA, Gosselies, Belgium and Consultant for Astellas Pharma Inc.

Funder

Ministry of Sustainable Development and Public Works

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2021.1893305

Reference88 articles.

1. Longitudinal Analysis of the Association Between Vasomotor Symptoms and Race/Ethnicity Across the Menopausal Transition: Study of Women’s Health Across the Nation

2. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition

3. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes

4. Healthcare seeking and treatment for menopausal symptoms in the United States

5. The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12

2. Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-11

3. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

4. Survey of patient experience and management of vasomotor symptoms due to menopause from the PatientsLikeMe community;Menopause;2024-09-10

5. The mechanism of action and chemical synthesis of FDA newly approved drug molecules;Drug Development Research;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3